Researchclopedia
Research
Researchers
Institutions
Topics
Submit
About
Search...
⌘
K
Command Palette
Search for a command to run...
Back to research
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
2016
631 citations
Journal Article
Field-Weighted Citation Impact:
77.13
·
Princess Margaret Cancer Centre
Janice P. Dutcher
·
Cancer Research Foundation
Michael B. Atkins
·
Vince Lombardi Cancer Clinic
Michael Pins
·
University of Illinois Chicago
George Wilding
·
The University of Texas MD Anderson Cancer Center
David Cella
·
Northwestern University
Lynne I. Wagner
·
Wake Forest University
Surena F. Matin
·
The University of Texas MD Anderson Cancer Center
Timothy M. Kuzel
·
Northwestern University
Wade J. Sexton
·
Moffitt Cancer Center
Yu-Ning Wong
·
Fox Chase Cancer Center
Toni K. Choueiri
·
Dana-Farber Cancer Institute
Роберто Пили
·
Indiana University – Purdue University Indianapolis
Igor Puzanov
·
Vanderbilt University
Manish Kohli
·
Mayo Clinic in Arizona
Walter M. Stadler
·
University of Illinois Chicago
Michael A. Carducci
·
Sidney Kimmel Comprehensive Cancer Center
Robert Coomes
·
Patient Advocate Foundation
Robert S. DiPaola
·
Rutgers, The State University of New Jersey
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Researchclopedia